Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pr

Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corp

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-s

Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's afte

SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensit

Gainers Veeva Systems (NYSE:VEEV) shares increased by 8.7% to $266.15 during Wednesday's after-

Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarco

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corpo

First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeu

Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospect

Company receives the Cancer Treatment Technology Innovator of the Year award SHELTON, Conn., May 14,

Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety report

Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospect

Company receives the Platinum Award for Innovator in Biotech Solutions Category SHELTON, Conn., Apri

Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalent

New US patent 12,496,345 strengthens the existing portfolio Patents now granted in 41 countries prot

Intensity Therapeutics Inc. (NASDAQ: INTS) on Thursday provided an update on the INVINCIBLE-4 Study.

Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) pat

SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Comp

Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19,